Delivers 11% Net Sales Growth; Raises and Tightens Full-Year 2026 Net Sales Guidance; Initiates Quarterly Dividend
Highlights
Second Quarter 2026
- Net sales of
$2,444 million , up 10.8% year-over-year- Adjusted Net Sales Growth1 of approximately 5% year-over-year
- Net income attributable to Versigent of
$118 million , up 10.3% year-over-year - Diluted Earnings Per Share of
$1.64 , Adjusted Diluted EPS1 of$1.92 - Adjusted EBITDA1 of
$272 million , up 24.8% year-over-year- Adjusted EBITDA1 margin of 11.1%, up 120 basis points year-over-year
- Net cash provided by operating activities of
$158 million , compared to$150 million in Q2 2025 - Free Cash Flow1 of
$107 million , relatively flat year-over-year - Board of Directors declared inaugural quarterly cash dividend of
$0.13 per share
Full Year 2026 Guidance
- Raised and tightened net sales guidance based on higher commodity pass-throughs and foreign currency impacts
- Reaffirmed guidance for Adjusted EBITDA1 and Free Cash Flow1
“Versigent’s solid second-quarter results demonstrate our continued ability to unlock greater value, even in a dynamic environment,” said
"Our double-digit net sales growth, underpinned by strong margins and cash generation, reflects the strength of our business and the value of our differentiated capabilities,” said
1) Non-GAAP measure - Refer to "Reconciliation of Non-GAAP Financial Measures” for a detailed reconciliation of these measures to the most directly comparable |
Second Quarter 2026 Results
Versigent delivered second quarter 2026 net sales of
Net income attributable to Versigent increased to
Adjusted EBITDA1 totaled
Interest expense totaled
Income tax expense for the quarter was
Net cash provided by operating activities totaled
Dividend
On
The declaration and payment of future dividends are subject to the discretion of the Company’s Board of Directors and will depend on the Company’s financial condition, results of operations, cash requirements, and other factors deemed relevant by the Board of Directors.
Updated Full Year 2026 Guidance
(in millions) | Current Guidance | Previous Guidance ( |
Net sales | ||
Adjusted EBITDA1,a | ||
Free Cash Flow1,a | ||
(a) Forward-looking non-GAAP measure. The Company does not provide a reconciliation of such forward-looking measure to the most directly comparable financial measure calculated and presented in accordance with | ||
Conference Call and Webcast
Versigent’s management team will host a conference call to discuss its second quarter 2026 financial results today,
A live webcast and related presentation materials will be available on Versigent’s Investor Relations website at ir.versigent.com. A replay of the webcast will be available on the same website approximately two hours after the call concludes.
To participate by telephone, please dial +1-800-330-6710 (
About Versigent
Versigent is a global leader in the purposeful design and advanced manufacturing of low and high voltage electrical architectures. Building on a legacy of engineering excellence and trusted partnerships, Versigent delivers versatile, intelligent solutions engineered to unlock greater capabilities for our customers. Powering one in six passenger vehicles in production today, Versigent’s high performance signal, power, and data distribution systems are trusted by industry leaders across automotive, commercial vehicles, agriculture and energy storage. With engineering and manufacturing centers on four continents and operations in more than 25 countries, Versigent’s approximately 138,000 employees match global scale with regional responsiveness to deliver consistent quality and reliable performance connecting the world to faster, smarter and safer experiences. Visit www.versigent.com.
Use of Non-GAAP Financial Measures
In addition to its reported results calculated in accordance with
Management believes these non-GAAP financial measures are useful to both management and investors in their analysis of the Company’s financial position, results of operations and liquidity. In particular, management believes Adjusted Net Sales Growth, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS and Free Cash Flow are useful measures in assessing the Company’s ongoing financial performance that, when reconciled to the corresponding
Such non-GAAP financial measures are reconciled to the most directly comparable
Forward-Looking Statements
This press release contains forward-looking statements that reflect, when made, Versigent’s current views with respect to current events, certain investments and acquisitions, business plans and financial performance. Such forward-looking statements are subject to many risks, uncertainties and factors relating to Versigent’s operations and business environment, which may cause the actual results of Versigent to be materially different from any future results, expressed or implied, by such forward-looking statements. All statements that address future operating, financial or business performance or Versigent’s strategies or expectations are forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “should,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Factors that could cause actual results to differ materially from these forward-looking statements include, but are not limited to, the following: disruptions in the supply of raw materials and other supplies integral to our products; future significant public health crises and other global health crises and the measures taken in response thereto; a prolonged recession and/or a downturn in global automotive sales; the volatile global economic environment and geopolitical conditions, including conditions affecting the credit market and global inflationary pressures; our reliance on relationships with collaborative partners and other third parties for product development and such parties’ failure to perform; employee strikes and labor-related disruptions involving us or one or more of our customers affecting our operations; fluctuations in interest rates and foreign currency exchange rates; our failure to comply with the numerous laws and regulations to which we are subject; adverse developments affecting one or more of our suppliers; any adverse impact of legal proceedings and disputes in which we are involved; challenges to our historical and future tax positions by taxing authorities; an increase in our tax burden due to ongoing or future tax audits; our failure to attract and retain key salaried employees and management personnel; our failure to manage the transition to a standalone public company; and our failure to achieve some or all of the benefits expected from the
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
(Unaudited) | |||||||||||||||
| Three Months Ended |
| Six Months Ended | ||||||||||||
|
| 2026 |
|
|
| 2025 |
|
|
| 2026 |
|
|
| 2025 |
|
| (in millions, except per share amounts) | ||||||||||||||
Net sales | $ | 2,444 |
|
| $ | 2,206 |
|
| $ | 4,656 |
|
| $ | 4,230 |
|
Operating expenses: |
|
|
|
|
|
|
| ||||||||
Cost of sales |
| 2,123 |
|
|
| 1,943 |
|
|
| 4,091 |
|
|
| 3,718 |
|
Selling, general and administrative |
| 100 |
|
|
| 104 |
|
|
| 197 |
|
|
| 209 |
|
Amortization |
| — |
|
|
| 1 |
|
|
| 1 |
|
|
| 1 |
|
Restructuring |
| — |
|
|
| 25 |
|
|
| 46 |
|
|
| 41 |
|
Separation costs |
| 22 |
|
|
| 2 |
|
|
| 48 |
|
|
| 7 |
|
Total operating expenses |
| 2,245 |
|
|
| 2,075 |
|
|
| 4,383 |
|
|
| 3,976 |
|
Operating income |
| 199 |
|
|
| 131 |
|
|
| 273 |
|
|
| 254 |
|
Interest expense |
| (36 | ) |
|
| (1 | ) |
|
| (41 | ) |
|
| (3 | ) |
Other expense, net |
| (6 | ) |
|
| — |
|
|
| (7 | ) |
|
| (1 | ) |
Income before income taxes and equity income |
| 157 |
|
|
| 130 |
|
|
| 225 |
|
|
| 250 |
|
Income tax expense |
| (46 | ) |
|
| (21 | ) |
|
| (37 | ) |
|
| (50 | ) |
Income before equity income |
| 111 |
|
|
| 109 |
|
|
| 188 |
|
|
| 200 |
|
Equity income, net of tax |
| 5 |
|
|
| 3 |
|
|
| 9 |
|
|
| 8 |
|
Net income |
| 116 |
|
|
| 112 |
|
|
| 197 |
|
|
| 208 |
|
Net (loss) income attributable to noncontrolling interest |
| (2 | ) |
|
| 5 |
|
|
| 1 |
|
|
| 6 |
|
Net income attributable to Versigent | $ | 118 |
|
| $ | 107 |
|
| $ | 196 |
|
| $ | 202 |
|
|
|
|
|
|
|
|
| ||||||||
Basic earnings per share: |
|
|
|
|
|
|
| ||||||||
Basic earnings per share attributable to Versigent | $ | 1.66 |
|
| $ | 1.51 |
|
| $ | 2.76 |
|
| $ | 2.85 |
|
Weighted average number of basic shares outstanding (1) |
| 70.90 |
|
|
| 70.89 |
|
|
| 70.90 |
|
|
| 70.89 |
|
|
|
|
|
|
|
|
| ||||||||
Diluted earnings per share: |
|
|
|
|
|
|
| ||||||||
Diluted earnings per share attributable to Versigent | $ | 1.64 |
|
| $ | 1.51 |
|
| $ | 2.75 |
|
| $ | 2.85 |
|
Weighted average number of diluted shares outstanding (1) |
| 71.88 |
|
|
| 70.89 |
|
|
| 71.39 |
|
|
| 70.89 |
|
(1) | For periods prior to the | |
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
|
|
|
| ||||
| (Unaudited) |
|
| ||||
| (in millions) | ||||||
ASSETS |
|
|
| ||||
Current assets: |
|
|
| ||||
Cash and cash equivalents | $ | 554 |
|
| $ | 276 |
|
Accounts receivable, net |
| 1,877 |
|
|
| 1,567 |
|
Inventories |
| 772 |
|
|
| 772 |
|
Other current assets |
| 337 |
|
|
| 158 |
|
Total current assets |
| 3,540 |
|
|
| 2,773 |
|
Long-term assets: |
|
|
| ||||
Property, net |
| 901 |
|
|
| 901 |
|
Operating lease right-of-use assets |
| 192 |
|
|
| 168 |
|
Investments in affiliates |
| 149 |
|
|
| 143 |
|
Intangible assets, net |
| 6 |
|
|
| 7 |
|
Deferred tax assets |
| 443 |
|
|
| 384 |
|
Other long-term assets |
| 128 |
|
|
| 109 |
|
Total long-term assets |
| 1,819 |
|
|
| 1,712 |
|
Total assets | $ | 5,359 |
|
| $ | 4,485 |
|
LIABILITIES AND EQUITY |
|
|
| ||||
Current liabilities: |
|
|
| ||||
Short-term debt | $ | 153 |
|
| $ | 58 |
|
Accounts payable |
| 1,666 |
|
|
| 1,530 |
|
Accrued liabilities |
| 713 |
|
|
| 578 |
|
Total current liabilities |
| 2,532 |
|
|
| 2,166 |
|
Long-term liabilities: |
|
|
| ||||
Long-term debt |
| 2,071 |
|
|
| 3 |
|
Pension benefit obligations |
| 214 |
|
|
| 217 |
|
Long-term operating lease liabilities |
| 144 |
|
|
| 130 |
|
Other long-term liabilities |
| 114 |
|
|
| 121 |
|
Total long-term liabilities |
| 2,543 |
|
|
| 471 |
|
Total liabilities |
| 5,075 |
|
|
| 2,637 |
|
Commitments and contingencies |
|
|
| ||||
Shareholders’ equity: |
|
|
| ||||
Preferred shares, |
| — |
|
|
| — |
|
Ordinary shares, |
| 1 |
|
|
| — |
|
Additional paid-in-capital |
| 143 |
|
|
| — |
|
Retained earnings |
| 118 |
|
|
| — |
|
Former Parent’s net investment |
| — |
|
|
| 1,925 |
|
Accumulated other comprehensive loss |
| (177 | ) |
|
| (268 | ) |
Total Versigent shareholders' equity |
| 85 |
|
|
| 1,657 |
|
Noncontrolling interest |
| 199 |
|
|
| 191 |
|
Total shareholders’ equity |
| 284 |
|
|
| 1,848 |
|
Total liabilities and shareholders’ equity | $ | 5,359 |
|
| $ | 4,485 |
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||
(Unaudited) | |||||||
| Six Months Ended | ||||||
| 2026 |
| 2025 | ||||
| (in millions) | ||||||
Net cash provided by operating activities | $ | 194 |
|
| $ | 190 |
|
Cash flows from investing activities: |
|
|
| ||||
Capital expenditures |
| (117 | ) |
|
| (79 | ) |
Net cash used in investing activities |
| (117 | ) |
|
| (79 | ) |
Cash flows from financing activities: |
|
|
| ||||
Net proceeds (repayments) under short-term debt agreements |
| 86 |
|
|
| (132 | ) |
Net repayments under long-term debt agreements |
| — |
|
|
| (1 | ) |
Proceeds from issuance of senior notes and credit agreement, net of issuance costs |
| 2,063 |
|
|
| — |
|
Cash distribution paid to Former Parent |
| (1,894 | ) |
|
| — |
|
Net transfers (to) from Former Parent |
| (47 | ) |
|
| 134 |
|
Dividend payments of consolidated affiliates to minority shareholders |
| (4 | ) |
|
| — |
|
Taxes withheld and paid on employees' restricted share awards |
| (1 | ) |
|
| — |
|
Net cash provided by financing activities |
| 203 |
|
|
| 1 |
|
Effect of exchange rate fluctuations on cash and cash equivalents |
| (2 | ) |
|
| 15 |
|
Increase in cash and cash equivalents |
| 278 |
|
|
| 127 |
|
Cash and cash equivalents at beginning of the period |
| 276 |
|
|
| 201 |
|
Cash and cash equivalents at end of the period | $ | 554 |
|
| $ | 328 |
|
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(Unaudited)
In this press release the Company has provided information regarding certain non-GAAP financial measures, including Adjusted Net Sales Growth, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS and Free Cash Flow. Such non-GAAP financial measures are reconciled to the most directly comparable
Adjusted Net Sales Growth: Adjusted Net Sales Growth is presented as a supplemental measure of the Company’s financial performance which management believes is useful to investors in assessing the Company’s ongoing financial performance that, when reconciled to the corresponding
| Three Months Ended |
| Six Months Ended | ||
|
|
|
| ||
Reported net sales year-over-year % change | 11 | % |
| 10 | % |
Less: impact of foreign currency movements | (2 | )% |
| (2 | )% |
Less: impact of commodity movements | (4 | )% |
| (4 | )% |
Adjusted Net Sales Growth | 5 | % |
| 4 | % |
Adjusted EBITDA: Adjusted EBITDA is presented as a supplemental measure of the Company’s financial performance which management believes is useful to investors in assessing the Company’s ongoing financial performance that, when reconciled to the corresponding
| Three Months Ended |
| Six Months Ended | ||||||||||||
| 2026 |
| 2025 |
| 2026 |
| 2025 | ||||||||
| (in millions) | ||||||||||||||
Net income attributable to Versigent | $ | 118 |
|
| $ | 107 |
|
| $ | 196 |
|
| $ | 202 |
|
Interest expense |
| 36 |
|
|
| 1 |
|
|
| 41 |
|
|
| 3 |
|
Income tax expense |
| 46 |
|
|
| 21 |
|
|
| 37 |
|
|
| 50 |
|
Net (loss) income attributable to noncontrolling interest |
| (2 | ) |
|
| 5 |
|
|
| 1 |
|
|
| 6 |
|
Depreciation and amortization |
| 51 |
|
|
| 59 |
|
|
| 112 |
|
|
| 111 |
|
EBITDA | $ | 249 |
|
| $ | 193 |
|
| $ | 387 |
|
| $ | 372 |
|
Other expense, net |
| 6 |
|
|
| — |
|
|
| 7 |
|
|
| 1 |
|
Equity income, net |
| (5 | ) |
|
| (3 | ) |
|
| (9 | ) |
|
| (8 | ) |
Restructuring |
| — |
|
|
| 25 |
|
|
| 46 |
|
|
| 41 |
|
Separation costs |
| 22 |
|
|
| 2 |
|
|
| 48 |
|
|
| 7 |
|
Net gain on lease terminations |
| — |
|
|
| — |
|
|
| (4 | ) |
|
| — |
|
Other acquisition and portfolio project costs |
| — |
|
|
| 1 |
|
|
| — |
|
|
| 3 |
|
Adjusted EBITDA | $ | 272 |
|
| $ | 218 |
|
| $ | 475 |
|
| $ | 416 |
|
Memo: |
|
|
|
|
|
|
| ||||||||
Net sales | $ | 2,444 |
|
| $ | 2,206 |
|
| $ | 4,656 |
|
| $ | 4,230 |
|
Net income margin |
| 4.8 | % |
|
| 4.9 | % |
|
| 4.2 | % |
|
| 4.8 | % |
Adjusted EBITDA margin |
| 11.1 | % |
|
| 9.9 | % |
|
| 10.2 | % |
|
| 9.8 | % |
Adjusted Net Income and Adjusted Diluted EPS: Adjusted Net Income and Adjusted Diluted EPS, which are non-GAAP financial measures, are presented as supplemental measures of the Company’s financial performance which management believes are useful to investors in assessing the Company’s ongoing financial performance that, when reconciled to the corresponding
| Three Months Ended |
| Six Months Ended | ||||||||||||
| 2026 |
| 2025 |
| 2026 |
| 2025 | ||||||||
| (in millions, except per share amounts) | ||||||||||||||
Net income attributable to Versigent | $ | 118 |
|
| $ | 107 |
|
| $ | 196 |
|
| $ | 202 |
|
Adjusting items: |
|
|
|
|
|
|
| ||||||||
Amortization |
| — |
|
|
| 1 |
|
|
| 1 |
|
|
| 1 |
|
Restructuring |
| — |
|
|
| 25 |
|
|
| 46 |
|
|
| 41 |
|
Separation costs |
| 22 |
|
|
| 2 |
|
|
| 48 |
|
|
| 7 |
|
Other acquisition and portfolio project costs |
| — |
|
|
| 1 |
|
|
| — |
|
|
| 3 |
|
Asset impairments |
| — |
|
|
| 3 |
|
|
| 7 |
|
|
| 3 |
|
Net gain on lease terminations |
| — |
|
|
| — |
|
|
| (4 | ) |
|
| — |
|
Pension curtailment and settlement losses |
| 2 |
|
|
| — |
|
|
| 6 |
|
|
| — |
|
Separation-related interest expense |
| — |
|
|
| — |
|
|
| 2 |
|
|
| — |
|
Tax impact of adjusting items (1) |
| (4 | ) |
|
| (5 | ) |
|
| (18 | ) |
|
| (8 | ) |
Adjusted Net Income | $ | 138 |
|
| $ | 134 |
|
| $ | 284 |
|
| $ | 249 |
|
|
|
|
|
|
|
|
| ||||||||
Weighted average number of diluted shares outstanding (2) |
| 71.88 |
|
|
| 70.89 |
|
|
| 71.39 |
|
|
| 70.89 |
|
Diluted earnings per share attributable to Versigent | $ | 1.64 |
|
| $ | 1.51 |
|
| $ | 2.75 |
|
| $ | 2.85 |
|
Adjusted Diluted EPS | $ | 1.92 |
|
| $ | 1.89 |
|
| $ | 3.98 |
|
| $ | 3.51 |
|
(1) | Represents the income tax impacts of the adjustments made for amortization, restructuring and other special items by calculating the income tax impact of these items using the appropriate tax rate for the jurisdiction where the charges were incurred. | |
(2) | For periods prior to the |
Free Cash Flow: Free Cash Flow is presented as a supplemental measure of the Company’s liquidity, which is consistent with the basis and manner in which management presents financial information for the purpose of making internal operating decisions, evaluating its liquidity and determining appropriate capital allocation strategies. Management believes this measure is useful to investors to understand how the Company’s core operating activities generate and use cash. Free Cash Flow is defined as net cash provided by (used in) operating activities less capital expenditures. Not all companies use identical calculations of Free Cash Flow, therefore this presentation may not be comparable to other similarly titled measures of other companies. The calculation of Free Cash Flow does not reflect cash used to service debt, pay dividends or repurchase shares and therefore, does not necessarily reflect funds available for investment or other discretionary uses.
| Three Months Ended |
| Six Months Ended | ||||||||||||
| 2026 |
| 2025 |
| 2026 |
| 2025 | ||||||||
| (in millions) | ||||||||||||||
Net cash provided by operating activities | $ | 158 |
|
| $ | 150 |
|
| $ | 194 |
|
| $ | 190 |
|
Capital expenditures |
| (51 | ) |
|
| (42 | ) |
|
| (117 | ) |
|
| (79 | ) |
Free Cash Flow | $ | 107 |
|
| $ | 108 |
|
| $ | 77 |
|
| $ | 111 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20260804545127/en/
Press Contact:
Vice President, Corporate Communications and Marketing
+1.248.817.7990
mediarelations@versigent.com
Investor Relations Contact:
Vice President, Investor Relations
erin.banyas@versigent.com
Source: